Tags

Type your tag names separated by a space and hit enter

Baloxavir heralds a new era in influenza virus biology.
Respir Investig. 2019 Jan; 57(1):1-2.RI

Abstract

Baloxavir marboxil is an orally available prodrug of baloxavir acid. Japan was the first country to approve baloxavir marboxil as a treatment for influenza. The antiviral mechanism of action of baloxavir is unique; the drug blocks initiation of viral mRNA synthesis, thus preventing proliferation of the influenza virus. A single oral dose of baloxavir is usually well tolerated; it hastens alleviation of influenza symptoms and shortens the duration of viral shedding. However, novel influenza variants exhibiting over 10-fold reductions in baloxavir susceptibility emerged in baloxavir-treated patients. Although further clinical investigation is required to explore this issue, baloxavir may revolutionize our understanding of influenza virus biology.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Kikuchi T
Department of Respiratory Medicine and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachidori, Niigata 951-8510, Japan. Electronic address: kikuchi@med.niigata-u.ac.jp.
Watanabe A
Research Division for Development of Anti-Infective Agents, Faculty of Medical Science and Welfare, Tohoku Bunka Gakuen University, Sendai 989-3203, Japan.

MeSH

Antiviral AgentsDepression, ChemicalDibenzothiepinsDrug Resistance, ViralHumansInfluenza A virusInfluenza B virusInfluenza, HumanMorpholinesOxazinesPyridinesPyridonesRNA, MessengerRNA, ViralThiepinsTriazinesVirus ReplicationVirus Shedding

Pub Type(s)

Editorial

Language

eng

PubMed ID

30396860

Citation

Kikuchi, Toshiaki, and Akira Watanabe. "Baloxavir Heralds a New Era in Influenza Virus Biology." Respiratory Investigation, vol. 57, no. 1, 2019, pp. 1-2.
Kikuchi T, Watanabe A. Baloxavir heralds a new era in influenza virus biology. Respir Investig. 2019;57(1):1-2.
Kikuchi, T., & Watanabe, A. (2019). Baloxavir heralds a new era in influenza virus biology. Respiratory Investigation, 57(1), 1-2. https://doi.org/10.1016/j.resinv.2018.10.002
Kikuchi T, Watanabe A. Baloxavir Heralds a New Era in Influenza Virus Biology. Respir Investig. 2019;57(1):1-2. PubMed PMID: 30396860.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Baloxavir heralds a new era in influenza virus biology. AU - Kikuchi,Toshiaki, AU - Watanabe,Akira, Y1 - 2018/11/03/ PY - 2018/09/06/received PY - 2018/10/15/accepted PY - 2018/11/7/pubmed PY - 2019/3/21/medline PY - 2018/11/7/entrez KW - Influenza KW - RNA polymerase PA subunit KW - Resistant variant KW - Viral shedding SP - 1 EP - 2 JF - Respiratory investigation JO - Respir Investig VL - 57 IS - 1 N2 - Baloxavir marboxil is an orally available prodrug of baloxavir acid. Japan was the first country to approve baloxavir marboxil as a treatment for influenza. The antiviral mechanism of action of baloxavir is unique; the drug blocks initiation of viral mRNA synthesis, thus preventing proliferation of the influenza virus. A single oral dose of baloxavir is usually well tolerated; it hastens alleviation of influenza symptoms and shortens the duration of viral shedding. However, novel influenza variants exhibiting over 10-fold reductions in baloxavir susceptibility emerged in baloxavir-treated patients. Although further clinical investigation is required to explore this issue, baloxavir may revolutionize our understanding of influenza virus biology. SN - 2212-5353 UR - https://www.unboundmedicine.com/medline/citation/30396860/Baloxavir_heralds_a_new_era_in_influenza_virus_biology_ DB - PRIME DP - Unbound Medicine ER -